Perforated and bleeding peptic ulcer : WSES guidelines by Tarasconi, Antonio et al.
REVIEW Open Access
Perforated and bleeding peptic ulcer: WSES
guidelines
Antonio Tarasconi1* , Federico Coccolini2, Walter L. Biffl3, Matteo Tomasoni4, Luca Ansaloni4, Edoardo Picetti5,
Sarah Molfino6, Vishal Shelat7, Stefania Cimbanassi8, Dieter G. Weber9, Fikri M. Abu-Zidan10, Fabio C. Campanile11,
Salomone Di Saverio12, Gian Luca Baiocchi6, Claudio Casella13, Michael D. Kelly14, Andrew W. Kirkpatrick15,
Ari Leppaniemi16, Ernest E. Moore17, Andrew Peitzman18, Gustavo Pereira Fraga19, Marco Ceresoli20,
Ronald V. Maier21, Imtaz Wani22, Vittoria Pattonieri1, Gennaro Perrone1, George Velmahos23, Michael Sugrue24,
Massimo Sartelli25, Yoram Kluger26 and Fausto Catena1
Abstract
Background: Peptic ulcer disease is common with a lifetime prevalence in the general population of 5–10% and
an incidence of 0.1–0.3% per year. Despite a sharp reduction in incidence and rates of hospital admission and
mortality over the past 30 years, complications are still encountered in 10–20% of these patients. Peptic ulcer
disease remains a significant healthcare problem, which can consume considerable financial resources.
Management may involve various subspecialties including surgeons, gastroenterologists, and radiologists. Successful
management of patients with complicated peptic ulcer (CPU) involves prompt recognition, resuscitation when
required, appropriate antibiotic therapy, and timely surgical/radiological treatment.
Methods: The present guidelines have been developed according to the GRADE methodology. To create these
guidelines, a panel of experts was designed and charged by the board of the WSES to perform a systematic review
of the available literature and to provide evidence-based statements with immediate practical application. All the
statements were presented and discussed during the 5th WSES Congress, and for each statement, a consensus
among the WSES panel of experts was reached.
Conclusions: The population considered in these guidelines is adult patients with suspected complicated peptic
ulcer disease. These guidelines present evidence-based international consensus statements on the management of
complicated peptic ulcer from a collaboration of a panel of experts and are intended to improve the knowledge
and the awareness of physicians around the world on this specific topic. We divided our work into the two main
topics, bleeding and perforated peptic ulcer, and structured it into six main topics that cover the entire management
process of patients with complicated peptic ulcer, from diagnosis at ED arrival to post-discharge antimicrobial therapy,
to provide an up-to-date, easy-to-use tool that can help physicians and surgeons during the decision-making process.
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Introduction
Peptic ulcer disease is common with a lifetime prevalence
in the general population of 5-10% and an incidence of
0.1–0.3% per year [1]. Peptic ulceration occurs due to acid
peptic damage to the gastro-duodenal mucosa, resulting in
mucosal erosion that exposes the underlying tissues to the
digestive action of gastro-duodenal secretions. This path-
ology was traditionally related to a hypersecretory acid en-
vironment, dietary factors and stress. However, the
increasing incidence of the Helicobacter pylori infection,
the extensive use of NSAIDs, and the increase in alcohol
and smoking abuse have changed the epidemiology of this
disease. Despite a sharp reduction in incidence and rates of
hospital admission and mortality over the past 30 years [2–
8], complications are still encountered in 10–20% of these
patients [9, 10]. Complications of peptic ulcer disease in-
clude perforation and bleeding and improvement in med-
ical management has made obstruction from chronic
fibrotic disease a rare event. A recent review on the epi-
demiology of complicated peptic ulcer disease [10] found
that hemorrhage was by far the most common complica-
tion of peptic disease, with a reported annual incidence of
hemorrhage in the general population ranging from 0.02 to
0.06%, with sample size-weighted average 30-day mortality
of 8.6%. Reported annual incidence of perforation ranges
from 0.004 to 0.014%, with sample size-weighted average
30-day mortality of 23.5%. Although perforation is less
common, with a perforation:bleeding ratio of approximately
1:6, it is the most common indication for emergency oper-
ation and causes about 40% of all ulcer-related deaths [11].
Peptic ulcer disease remains a significant healthcare
problem, which can consume considerable financial re-
sources. Management may involve various subspecialties
including surgeons, gastroenterologists, and radiologists.
Successful management of patients with complicated
peptic ulcer (CPU) involves prompt recognition, resusci-
tation when required, appropriate antibiotic therapy and
timely surgical/radiological treatment.
Notes on the use of the guidelines: aims, targets, and
limitations
The Guidelines are aimed to present the state-of-the-art re-
garding diagnosis and therapeutic options for an optimal
management of complicated peptic ulcer. These guidelines
are thus intended to improve the knowledge and the aware-
ness of physicians around the world on the specific topic of
complicated peptic ulcer, providing an up-to-date tool that
can help during the decision-making process. For this rea-
son, the Guidelines are evidence-based and the grade of
recommendation is provided to summarize the evidences
present in literature. The population considered in these
guidelines is adult patients with suspected complicated pep-
tic ulcer disease. The practice Guidelines promulgated in
this work do not represent a standard of practice. They are
suggested plans of care, based on best available evidence
and the consensus of experts but they do not exclude other
approaches as being within the standard of practice. For ex-
ample, they should not be used to compel adherence to a
given method of medical management, which method
should be finally determined after taking account of the
conditions at the relevant medical institution (staff levels,
experience, equipment, etc.) and the characteristics of the
individual patient. However, responsibility for the results of
treatment rests with those who are directly engaged therein,
and not with the consensus group.
Methods
These consensus guidelines are an update of the 2013
WSES position paper on this topic. To create these guide-
lines, a panel of experts was designed and charged by the
board of the WSES to develop questions on six main
topics that thoroughly cover the field of this pathology
(diagnosis, resuscitation, nonoperative management, sur-
gery, angiography-angioembolization, antimicrobial ther-
apy). Then, leading specialists in the field were asked to
perform a thorough search on each of these topics in dif-
ferent databanks (MEDLINE, SCOPUS, EMBASE) for
relevant papers between 1985 and June 2018 and a sys-
tematic review of the available literature. They were asked
to focus their search in order to provide evidence-based
answers to every question with immediate practical appli-
cation and to summarize them in statements. All the
statements were presented and discussed during the 5th
WSES Congress held in Bertinoro, Italy in June 28th,
2018. For each statement, a consensus among the WSES
panel of experts was reached. All the members contrib-
uted to the development of the manuscript; the manu-
script was reviewed and approved by all the authors.
The present guidelines have been developed according
to the GRADE methodology [12, 13].
Topics and questions
For clarity, we report the six topics together with the
questions dividend into each of them.
Diagnosis
1. In patients with a suspected perforated peptic ulcer,
which are the appropriate biochemical and imaging
investigations that should be requested?
2. In patients with perforated peptic ulcer, what is the
clinical value of risk scores such as Boey Score and
Pulp score?
3. In patients with suspected bleeding peptic ulcer,
which biochemical and imaging investigations
should be requested?
4. In patients with suspected bleeding peptic ulcer,
what is the diagnostic role of endoscopy?
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5. In patients with bleeding peptic ulcer, are the
endoscopic findings useful to determine the risk for
rebleeding and how do they affect the clinical
management?
Resuscitation
1. In patients with perforated peptic ulcer, which
parameters should be evaluated ad ED referral?
2. In patients with perforated peptic ulcer, which are
the appropriate targets for resuscitation
(hemoglobin level, blood pressure/heart rate,
lactates level, others)?
3. In patients with bleeding peptic ulcer, which
parameters should be evaluated at ED referral and
which criteria should be adopted to define an
unstable patient?
4. In patients with bleeding peptic ulcer, which are the
appropriate targets for resuscitation (hemoglobin level,
blood pressure/heart rate, lactates level, others)?
Non-operative management—endoscopic treatment
1. In patients with perforated peptic ulcer, which are
the indications for non-operative management?
2. In patients with perforated peptic ulcer, is there a
role for endoscopic treatment?
3. In patients with bleeding peptic ulcer, which are the
indications for non-operative management?
4. In patients with bleeding peptic ulcer, which are the
indications for endoscopic treatment?
5. In patients with bleeding peptic ulcer, what is the
appropriate pharmacological regimen
(Erythromycin, PPI, terlipressin, others)?
6. In patients with recurrent bleeding from peptic ulcer,
what is the role of non-operative management?
Angiography–embolization
1. In patients with bleeding peptic ulcer, which are the
indications for angiography?
2. In patients with bleeding peptic ulcer, which are the
indications for angioembolization?
3. Should embolization be considered for unstable
patients with bleeding peptic ulcer?
4. In patients with recurrent bleeding peptic ulcer,
which are the indications for angioembolization?
5. In patients who underwent angioembolization,
which are the most appropriate embolization
techniques and materials?
6. In patients with bleeding peptic ulcer and non-
evident bleeding during angiography is there a role
for prophylactic embolization?
Surgery
1. In patients with perforated peptic ulcer, which are
the indications for surgical treatment and what is
the appropriate timing for surgery?
2. In patients with perforated peptic ulcer what is the
most appropriate surgical approach (open vs
laparoscopy)?
3. In patients with perforated peptic is there a role for
sutureless repair?
4. In patients with perforated peptic ulcer and small
perforation (< 2 cm), which surgical procedure
should be adopted?
5. In patients with perforated peptic ulcer and large
perforation (≥ 2 cm), which surgical procedure should
be adopted?
6. In patients with perforated peptic ulcer, what is the
role of damage control surgery?
7. In patients with bleeding peptic ulcer, which are the
indications for surgical treatment and which is the
appropriate timing for surgery?
8. In patients with bleeding peptic ulcer, what is the
most appropriate surgical approach (open vs
laparoscopy) and what are the most appropriate
surgical procedures?
9. In patients with bleeding peptic ulcer, what is the
role of damage control surgery?
Antimicrobial therapy
1. Should antibiotic therapy be prescribed and should
anti-fungal therapy be administrated empirically in
patients with perforated peptic ulcer?
2. In patients with perforated peptic ulcer, which
antimicrobial regimen should be used and what is
its correct duration?
3. In patients with bleeding peptic ulcer, which are the
indications for antimicrobial therapy and for
Helicobacter pylori testing?
4. In patients with bleeding peptic ulcer and positive
tests for H. pylori infection, which are the
therapeutic options?
Perforated peptic ulcer
Diagnosis
In patients with a suspected perforated peptic ulcer,
which are the appropriate biochemical and imaging
investigations that should be requested?
In patients with suspected gastroduodenal
perforation, we recommend routine laboratory
studies and arterial blood gas analysis (strong
recommendation based on very low-quality evi-
dences, 1D).
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In patients with acute abdomen from suspected
perforated peptic ulcer, we recommend a CT scan
imaging (Strong recommendation based on low-
quality evidences, 1C).
In patients with acute abdomen from suspected
perforated peptic ulcer, we recommend to perform
chest/abdominal X-ray as the initial routine diagnostic
assessment in case a CT scan is not promptly available
(Strong recommendation based on low-quality evi-
dences, 1C).
In patients with acute abdomen from suspected
perforated peptic ulcer, when free air is not seen on
imaging and there is ongoing suspicion of perforated
peptic ulcer, we suggest performing imaging with the
addition of water-soluble contrast either oral or via
nasogastric tube (weak recommendation based on very
low-quality evidences, 2D).
The clinical presentation of gastroduodenal perforation is
usually sudden onset of abdominal pain. Localized or gen-
eralized peritonitis is typical of perforated peptic ulcer, but
may be present in only two-thirds of the patients [14–16].
Thus, physical examination findings may be equivocal and
peritonitis may be minimal or absent, particularly in pa-
tients with contained and / sealed leak. Laboratory tests are
non-specific, although leukocytosis, metabolic acidosis and
elevated serum amylase are usually associated with perfor-
ation [17]. The first diagnostic investigation is the radio-
graph of the abdomen and chest, to detect the presence of
free abdominal air. Erect and left lateral decubitus X-rays
have similar diagnostic accuracy, the latter being better tol-
erated by patients presenting with peritonitis. The presence
of this radiological sign is highly variable across various
studies present in literature and ranges between 30 and
85% of perforations. This high variability and the finding
that a negative X-ray does not rule out a possible perfor-
ation led multiple authors to state that, in case of clear signs
of peritonitis, an abdominal CT scan should be the first
radiological examination to be performed. However, in the
setting of a peripheral hospital without prompt access to a
CT scan, the plain X-ray still has a diagnostic role and free
air on X-ray associated with a clear history and signs of
peritonitis on physical examination is sufficient to justify
surgical exploration [9, 14, 15, 18]. An adjunct to plain X-
ray could be the administration through a nasogastric tube
(NGT) of water-soluble contrast that can detect the pres-
ence of a gastro-duodenal perforation. “Point-of-care” ultra-
sound could also detect free intra-peritoneal, when
performed by a trained operator, with the demonstration of
air under the abdominal fascia; anyway, its role in the diag-
nostic work-up of suspected perforated peptic ulcer still
needs to be defined. Suspicious CT scan findings include
unexplained intraperitoneal fluid, pneumoperitoneum,
bowel wall thickening, mesenteric fat streaking, and pres-
ence of extraluminal water-soluble contrast. Indeed, CT
scan is increasingly taking the main role in diagnosis of per-
foration, due to the greater sensitivity in detecting free air
and to its ability to characterize the site and size of perfor-
ation and to exclude other possible causes [15, 18, 19].
However, up to 12% of patients with perforations may have
a normal CT scan; in this scenario, the administration of
oral water-soluble contrast or via nasogastric tube and per-
forming triple contrast CT scan may improve diagnostic
sensitivity and specificity [17].
In patients with perforated peptic ulcer, what is the
clinical value of risk scores such as Boey Score and
Pulp score?
In patients with perforated peptic ulcer, we suggest to
adopt scoring systems (including the Boey, PULP and
ASA score) for risk-stratification of patients and to pre-
dict outcomes (weak recommendation, based on low-
quality evidences, 2C).
Numerous scoring systems have been designed and vali-
dated with the aim of predicting mortality and morbidity in
patients with perforated peptic ulcer [20–22]. The Boey
score is the most used, followed by the ASA score and the
PULP. Boey's score showed an elevated variability in accur-
acy across the different studies where it was tested. On the
other hand, the PULP score is difficult to apply and has not
yet been validated outside the initial center. The new PULP
score and the ASA score predicted mortality equally well
and better than the Boey score, but hypoalbuminemia still
remains the strongest single predictor of mortality [20–22].
Resuscitation
In patients with perforated peptic ulcer, which pa-
rameters should be evaluated ad ED referral?
We recommend prompt evaluation and early
recognition of the patient with perforated peptic ulcer
associated sepsis to prevent further organ failure and
to reduce mortality (strong recommendation based on
moderate-quality evidences, 1B).
We suggest adopting scoring systems (SOFA, qSOFA) to
evaluate and assess the severity of the disease in patients
with perforated peptic ulcer (Weak recommendation
based on low-quality evidences, 2 C).
Perforated peptic ulcer, with associated peritonitis and
sepsis/septic shock, is a medical/surgical emergency requir-
ing rapid evaluation and management [23]. It is crucial to
identify parameters to assess the severity of the disease (i.e.,
to define if a patient is stable or unstable). The latest
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definition of sepsis/septic shock and related debates/contro-
versies are beyond the scope of this manuscript but are cov-
ered in recent papers [24, 25]. The timely recognition of
sepsis (i.e., before the occurrence of organ dysfunction) is a
priority [25, 26]. During the ED evaluation of every septic
patient, several elements should be considered to assess the
clinical picture. Specifically, several symptoms (i.e., altered
mental state, dyspnea), signs (i.e., tachycardia, tachypnea,
reduced pulse pressure, decreased urine output) and labora-
tory findings (hyperlactatemia, arterial hypoxemia, in-
creased creatinine, coagulation abnormalities) must be
evaluated. It is important to keep in mind that these find-
ings may be modified by preexisting disease or medications
[27]; for this reason, the collection of clinical history needs
to be performed carefully.
Scoring systems, i.e., the sequential organ failure as-
sessment (SOFA) [28] or the quick SOFA (qSOFA) [29],
with associated limitations [25, 30–33], are available to
assess the severity of the disease.
In patients with perforated peptic ulcer, which are
the appropriate targets for resuscitation (hemoglobin
level, blood pressure/heart rate, lactates level, others)?
In unstable patients with perforated peptic ulcer, we
recommend performing rapid resuscitation to reduce
mortality (strong recommendation based on low
quality evidences, 1C).
In unstable patients with perforated peptic ulcer, we
recommend restoring physiological parameters with a
mean arterial pressure ≥ 65 mmHg, a urine output ≥
0.5 ml/kg/h, and a lactate normalization) (strong
recommendation based on low-quality evidences,1C).
We suggest utlizing different types of hemodynamic
monitoring (invasive or not) to optimize fluids/
vasopressor therapy and to individualize the
resuscitation strategy (strong recommendation based
on low quality evidences, 1C).
Unstable septic perforated peptic ulcer patients need ap-
propriate and rapid (ideally within 1 h) resuscitation to re-
duce mortality [27, 29]; this must take place simultaneously
with surgical consultation, microbiological cultures (blood
and other), and antibiotic administration [24, 34]. Primarily,
as in any emergency situation, a rapid ABC (airway, breath-
ing, and circulation) evaluation should be done. Secondar-
ily, appropriate targets for resuscitation (the same used for
sepsis and septic shock [27, 35]) need to be considered. In
general, the most important are:
– Mean arterial pressure (MAP) ≥ 65 mmHg
– Urine output ≥ 0.5 ml/kg/h
– Lactate normalization
Several forms of hemodynamic monitoring (invasive or
not) are available to optimize resuscitation and fluid/va-
sopressors administration. For a more comprehensive
approach to sepsis and septic shock, we suggest referring
to the last published guidelines of the “Surviving Sepsis
Campaign” [35].
Non-operative management—endoscopic treatment
In patients with perforated peptic ulcer, which are
the indications for non-operative management?
In patients with perforated peptic ulcer we suggest
against a routinely use of non-operative management;
non-operative management (NOM) could be consid-
ered in extremely selected cases where perforation has
sealed as confirmed on water-soluble contrast study
(weak recommendation based on low-quality evi-
dences, 2C).
Non-operative management (NOM) of perforated pep-
tic ulcer is attractive as it avoids surgery and its resultant
morbidity, e.g., wound-related morbidity, postoperative
adhesions, etc. The rationale of NOM is that, in the case
of small perforations, the ulcer seals by omental adhesions
and can then heal and the peritonitis does not need oper-
ation [36]. In 1989 Croft et al. conducted a prospective
randomized trial [37] comparing emergency surgery and
NOM in patients with a clinical diagnosis of perforated
peptic ulcer: 83 patients were entered in the study over a
period of 13months and were randomly assigned to one
the two study groups. In the NOM group, 11 patients (28
percent) had no clinical Improvement after 12 h and re-
quired an operation. The overall mortality rates in the two
groups were similar (two deaths in each, 5%), and did not
differ significantly in the morbidity rates (40% in the surgi-
cal group and 50% in the nonsurgical group). The hospital
stay was 35% longer in the group treated conservatively
and patients over 70 years old were less likely to respond
to conservative treatment than younger patients (p <
0.05). Songne et al. in 2004 [38] conducted a prospective
trial of 82 consecutive patients with diagnosis of perfo-
rated peptic ulcer; they initially underwent NOM and clin-
ical improvement was achieved in 54% of patients after
NOM. In multivariate analysis, the factors independently
related to NOM failure were size of pneumoperitoneum,
heart rate > 94 bpm, and abdominal meteorism (defined
as distended bowel loops). In conclusion, the most im-
portant factors regarding the feasibility of NOM for perfo-
rated peptic ulcer are normal vital signs in a stable patient
and whether the ulcer itself has sealed as confirmed by a
water-soluble contrast study: if there is a free leak of con-
trast, surgery is needed. On the other hand, NOM could
be considered if no contrast extravasation is present and
the patient does not have signs of peritonitis or sepsis.
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The essential pre-requisites and components of non-
operative management of PPU can be grouped as “R”s [39]:
– Radiologically undetected leak
– Repeated clinical examination
– Repeated blood investigations
– Respiratory and renal support
– Resources for monitoring and
– Readiness to operate
NOM includes: nil by mouth; intravenous hydration;
decompression via nasogastric tube; anti-secretory and
PPI therapy; intravenous antibiotics; and follow-up en-
doscopy at 4–6 weeks. Mortality increases with every
hour of delay to surgery, and hence, NOM must be care-
fully selected. Surapaneni et al. have shown nil mortality
in patients who were operated within 24 h of onset of
symptoms as compared to surgery beyond 48 h of onset
of symptoms [40]. Buck et al. in 2688 Danish patients
have shown that every hour of delay from admission to
surgery was associated with an adjusted 2.4% decreased
probability of survival compared with the previous hour
[41]. Elderly patients may experience paradoxical higher
mortality if non-operative management fails and caution
is advised in patients > 70 years of age.
In patients with perforated peptic ulcer is there a
role for endoscopic treatment?
In patients with perforated peptic ulcer, we suggest to
avoid endoscopic treatment such clipping, fibrin glue
sealing, or stenting (Weak recommendation based on
low-quality evidences, 2C)
Closure of acute iatrogenic perforations with endo-
scopic clips is described [42, 43]; however, clips may not
be effective in perforated ulcer cases due to fibrotic tis-
sue with loss of compliance. Combined laparoscopic-
endoscopic approaches for perforated ulcer closures
have been described [44, 45]. Bergstrom et al. [46]
present a case series of eight patients with perforated
duodenal ulcers treated with covered self-expandable
metal stents and the results indicate that, in very se-
lected patients or in cases where surgical closure will be
difficult, gastroscopy with stent placement could be per-
formed during laparoscopy, followed by laparoscopic
drain placement. In patients with severe co-morbidity or
delayed diagnosis, gastroscopy and stent placement
followed by radiologically guided drain placement could
be an alternative to more standard treatment. Endo-
scopic snaring of omentum and pulling is also described
as an effective adjunct along with duodenal plication.
Furthermore, endoscopy also allows performing a biopsy
and rule out gastric outlet obstruction in case of large
perforations. In spite of these case series, all the above
reported modalities are not recognized as standard ap-
proaches to perforated peptic ulcer and need further
validation.
Surgery
In patients with perforated peptic ulcer, which are
the indications for surgical treatment and what is the
appropriate timing for surgery?
In patients with perforated peptic ulcer with
significant pneumoperitoneum or extraluminal
contrast extravasation or signs of peritonitis, we
recommend operative treatment (Strong
recommendation based on low-quality evidences, 1C)
We recommend performing surgery as soon as
possible, especially in patients with delayed
presentation and patients older than 70 years old
(strong recommendation based on moderate-quality
evidences, 1B)
The feasibility of NOM should be weighed with the evi-
dence that an increase in surgical delay significantly impairs
surgical outcome. In fact, a cohort study performed in 2013
from the Danish Clinical Register of Emergency Surgery
[41] showed that, over the first 24 h after admission, each
hour of surgical delay beyond hospital admission was asso-
ciated with an adjusted 2.4% decreased probability of sur-
vival compared with the previous hour, over the entire
observation period. Other studies highlighted the import-
ance of a prompt surgical approach to PPU: a retrospective
single-center study by Lunevicious et al. [47] showed an in-
crease in the suture leakage rate after a delay in presenta-
tion > 9 h, while a recent prospective single-center study on
101 patients with peritonitis from peptic ulcer perforation
who underwent laparotomy and simple closure with omen-
tal patch found that a perforation-to-surgery interval longer
than 36 h was significantly associated with an increase in
postoperative mortality [48]. Furthermore, a systematic re-
view [49] performed in 2010 including fifty studies with 37
prognostic factors comprising a total of 29,782 patients pro-
vided strong evidence for an association of older age, co-
morbidity, and use of NSAIDs or steroids with mortality;
shock upon admission, preoperative metabolic acidosis,
tachycardia, acute renal failure, low serum albumin level,
high ASA score, and preoperative delay > 24 h were also as-
sociated with poor prognosis. Limiting pre-operative delay
thus seems to be of great importance.
In patients with perforated peptic ulcer, which is
the most appropriate surgical approach (open vs
laparoscopy)?
In stable patients with perforated peptic ulcer, we suggest a
laparoscopic approach. An open approach is
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recommended in the absence of appropriate laparoscopic
skills and equipment (weak recommendation based on
moderate-quality evidences, 2B).
In unstable patients with perforated peptic ulcer, we
recommend open surgery (strong recommendation
based on very low-quality of evidences, 1D)
A recent meta-analysis from Cirocchi et al. [50] com-
pared laparoscopic to open surgery for patients with per-
forated peptic ulcer: their search identified 8 RCTs for a
total of 615 patients (307 patients undergoing laparoscopic
repair and 308 patients undergoing open repair); however
all the included studies were at high risk of bias. The com-
parison reported a significant advantage of laparoscopic
repair with less postoperative pain in the first 24 h after
surgery and less postoperative wound infections. No sig-
nificant differences between laparoscopic and open sur-
gery were found for overall postoperative mortality, leak
of the suture repair, intra-abdominal abscesses and reop-
eration rate. This is the strongest evidence present so far
the literature and suggests it is reasonable to pursue a lap-
aroscopic approach for stable patients and in the presence
of appropriate surgical skills.
The effects of increased intra-abdominal pressure and
hypercarbia due to CO2 insufflation during laparoscopy are
well known (increased systemic vascular resistance, mean
arterial pressure, afterload, heart rate, caval pressures, re-
spiratory rate, peak airways pressure, PaCO2; reduced
stroke volume, venous return, cardiac output, thoracic
compliance, pH) [51] and preclude a laparoscopic approach
to hemodynamically unstable patients or patients with se-
vere cardiovascular or pulmonary comorbidity.
Is there a role for sutureless repair in patients with
perforated peptic ulcer?
Based on the available literature, no recommendation
could be made about the sutureless repair.
Sutureless repair was proposed with the rationale to
shorten operative time and to simplify the surgical tech-
nique, making it easily performed by those who have
limited experience with laparoscopic surgery. However,
it has not gained a wide acceptance due to its high leak-
age rate compared to suture repair. A prospective study
conducted from January 1992 to December 1998 in-
cluded 374 patients with perforated peptic ulcer [52];
219 patients were treated by open suture repair, 109 pa-
tients received laparoscopic fibrin glue repair and the
remaining 46 patients were treated by laparoscopic su-
ture repair. Laparoscopic fibrin glue repair was initially
attempted in 149 patients but 40 required conversion to
suture repair. The overall conversion rates for laparo-
scopic fibrin glue repair and laparoscopic suture repair
were 27 and 15%, respectively. The main reasons for
conversion were a large (1 cm or more) ulcer perforation
and failure to locate the perforation site. The overall leak
rates after laparoscopic glue repair and laparoscopic su-
ture repair were 16 and 6% respectively and the reopera-
tion rates for clinical leaks after laparoscopic glue repair
and laparoscopic suture repair were 10 and 4% respect-
ively. On the other hand, a retrospective cohort study
performed from January 2008 to December 2012 found
conflicting results [53]: 107 patients were included, 64
underwent laparoscopic repair with a sutureless on-lay
omental patch, and 43 were treated by laparoscopic su-
tured omental patch. High-risk patients with Boey scores
of 2 and 3 or those with perforations larger than 10mm
were excluded. The time to water intake was signifi-
cantly shorter for patients who had repair with a suture-
less omental patch (p = 0.007), as well as the mean
hospital stay (p = 0.007). All patients in both groups sur-
vived to the end of the study and no patient experienced
leakage after the operation. The evidences listed above
are based on low quality studies and do not allow us to
make a recommendation for its routine application.
In patients with perforated peptic ulcer and small
perforation (< 2 cm), which surgical procedure should
be adopted?
In patients with perforated peptic ulcer smaller than 2
cm, we suggest performing primary repair. No
recommendation can be made whether the use of an
omental patch can provide further protection of the
repair (weak recommendation based on low-quality
evidences, 2C)
Historically, repair with the adjunct of an omental
patch was considered the “standard” laparoscopic pro-
cedure for perforated peptic ulcer repair. This belief is a
now matter of debate as multiple studies showed the
addition of an omental patch does not add benefits to a
simple suture repair, but it significantly increases the op-
eration time.
Multiple retrospective single-center studies support these
findings. Lin et al. [54] analyzed 118 patients with PPU who
underwent laparoscopic repair with simple closure (n = 27)
or omentopexy (n = 91) and found Three closure leakage:
1 after simple closure and 2 after omentopexy, but no pa-
tient died. After matching, the simple closure and omento-
pexy groups had comparable results regarding leakage rate.
Comparison of the operating time in the 4.0- and 5.0–12-
mm groups reported that the simple closure took less time
than omentopexy for perforations smaller than 12mm.
Abd Ellatif and colleagues [55] enrolled 179 consecutive pa-
tients with PPU who were treated by laparoscopic repair;
108 patients with the omental patch technique and 71 with
laparoscopic simple repair. Operative time was significantly
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shorter in the non-patch group and no patient was con-
verted to laparotomy. There was no difference in age, gen-
der, ASA score, surgical risk (Boey’s) score, and incidence
of co-morbidities between two groups and both groups was
comparable in terms of hospital stay, time to resume oral
intake, postoperative complications and surgical outcomes.
Lo et al. retrospectively identified 73 patients undergoing
PPU laparoscopic repair, 26 received simple closure repair
and 47 received simple closure plus omental patch. There
was no difference in age, gender, ASA score, Boey risk
score, incidence of co-morbidities, Mannheim Peritonitis
index, median operation time or length of stay. Again, they
stated that, in terms of leakage rate and surgical outcome,
the maneuver to cover an omental patch on the repaired
PPU did not show additional advantage compared to sim-
ple closure alone [56]. A multicenter non-randomized
retrospective study [57] further strengthens these findings:
between 2009 and 2013, 297 patients with PPU underwent
a laparoscopic procedure in eight Romanian surgical cen-
ters. Primary suture repair was performed in 145 patients
(48.8%), primary suture repair with omentopexy in 146 pa-
tients (49.2%) and the remaining 6 patients were converted
to open surgery. The univariate complications rate analysis
they performed found no significant association (p = 0.634;
Fisher’s exact test) between the type of the repair and the
rate of complications. A prospective non-randomized study
by Ates et al. compared laparoscopic simple closure with
conventional omental patch open repair for perforated pep-
tic ulcer. Of the 35 patients enrolled, none experienced op-
erative complications nor postoperative leak or residual
intra-abdominal abscess [58]. On the other hand, multiple
retrospective studies highlight low postoperative leak rates
with the omental patch technique, even in case of perfora-
tions up to 2 cm in diameter [59]. Multiple authors suggest
the adjunct of an omental patch in case of large ulcers with
friable edges, to reduce the risk of the suture cutting
through the edges of the ulcer [60].
In light of the above, we cannot suggest the routine
application of the omental patch because of the longer
operative time, the need for advanced laparoscopic skills
and the similar results after simple closure, but it could
be considered a viable option in selected cases.
In patients with perforated peptic ulcer and large
perforation (≥ 2 cm), which surgical procedure should
be adopted?
We suggest a tailored approach based upon the
location of the ulcer for the treatment of perforated
peptic ulcer larger than 2 cm. In case of large gastric
ulcers that raise the suspicion of malignancy, we
suggest resection with contextual operative frozen
pathologic examination whenever possible. In case of
large duodenal ulcers, we suggest considering the need
of resections or repair plus/minus pyloric exclusion/
external bile drainage. We recommend duodenostomy
only in extreme circumstances (weak recommendations
based on very low-quality evidences, 2D).
While the treatment of a small ulcer is relatively
straightforward, the treatment of giant peptic ulcers
(diameter > 2 cm) poses different challenges according
to the anatomical location. Furthermore, large gastric ul-
cers should always raise the suspicion of malignancy
[61]. The spontaneous perforation of gastric cancer is a
rare complication, occurring in 1% of patients with gas-
tric cancer, and it has been reported that about 10–16%
of all gastric perforations are caused by gastric carcin-
oma [62]. Besides this, there are no specific surgical
treatment recommendations since the site of perforation
and the secondary effects on the surrounding anatomical
structures must direct the necessary interventions. The
gastric location is usually easier to treat when compared
to the duodenal location and gastric resection and re-
construction should be the surgical choice for the treat-
ment of perforated gastric ulcers larger than 2 cm. On
the other hand, only the first portion of the duodenum
can be resected easily without risk of injuring the bile
duct or the pancreatic head. Antrectomy plus or minus
D1–D2 resection with diversion is the classic and most
commonly described intervention, if the ampullary re-
gion is not involved [63]. The proximity of the defect
and its relation to the common bile duct and ampulla of
Vater must also be thoroughly investigated and intraop-
erative cholangiography may even be necessary to verify
common bile duct anatomy. Several different proce-
dures, such as a jejunal serosal patch, Roux en-Y duode-
nojejunostomy, pyloric exclusion, and several variations
of omental plugs [64] have been described for large duo-
denal defects when the defect is felt too large to perform
a primary repair. In large ulcers, leak rates up to 12%
have been reported from attempted closure with an
omental patch procedure [65]. These patients also fre-
quently present in septic shock when the amount of
peritoneal spillage is large. This factor alone should sig-
nificantly influence the choice of operative intervention,
because a definitive resectional approach for ulcers in-
volving the ampullary area (i.e., Whipple procedure or
similar) is usually not recommended in patients with
peritonitis, because of the high physiological impact of
these procedures and the great risk of postoperative
complications. In these cases, a damage control proced-
ure (such as pyloric exclusion with gastric decompres-
sion via a nasogastric tube or a gastrostomy and an
external biliary diversion via T-tube) will likely be the
safest and most appropriate operation for the patient
[66]. Duodenostomy (e.g., over Petzer tube) should be
used only as a last resort, in the presence of giant ulcers
with severe tissue inflammation and when mobilization
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of the duodenum is not possible and the patient is in se-
vere septic shock with hemodynamic instability.
In patients with perforated peptic ulcer, what is the
role of damage control surgery?
In patients with septic shock from a perforated
peptic ulcer and signs of severe physiological
derangement, we suggest a damage control strategy
(Weak recommendation based on very low-quality
of evidences, 2D)
In severe peritonitis, some patients may experience
disease progression to severe sepsis and septic shock ex-
periencing progressive organ dysfunction, hypotension,
myocardial depression, and coagulopathy and a staged
approach may be required. If the patient is not in a con-
dition to undergo a definitive repair and/or abdominal
wall closure, due to mandatory conditions requiring an
open abdomen, the intervention should be abbreviated
due to suboptimal local conditions for healing and global
susceptibility to spiraling organ failure [67]. Such
mandatory conditions include physical inability to close
the abdominal fascia without tension, a decision to leave
intra-abdominal packing, or a decision to leave blind
bowel loops to expedite the procedure. Committing a
patient to an open abdomen however has significant
risks including the most feared enteroatmospheric fistula
which has been reported to be more common in emer-
gency general surgery patients than trauma patients.
“Source control” of intra-abdominal contamination re-
mains a discretionary reason to leave the abdomen open,
recognizing that “inability to achieve source control” is a
frequently quoted but poorly objectified concept in
emergency general surgery. Although upper gastrointes-
tinal perforations are often less catastrophic than lower
gastrointestinal contaminations, when the patient
responded with immunological activation and systemic
sepsis, they are suffering from severe complicated intra-
abdominal sepsis. If these conditions are met, then we
suggest participation and potential enrollment in the
COOL Trial [68–70] Closed or Open after Laparot-
omy (COOL) study (https://clinicaltrials.gov/ct2/
show/NCT03163095) to help provide better guidance
for clinicians in the future treating such challenging
patients. In general, anastomoses should be avoided in
the presence of hypotension or hemodynamic instabil-
ity, especially if the patient requires vasopressors.
After copious abdominal irrigation, a temporary ab-
dominal closure device can be placed if there are
mandatory factors dictating an OA or if the patient is
randomized to this therapy in the COOL trial. The pa-
tient can then be resuscitated appropriately in the
ICU. The surgeon can return to the OR for re-
exploration, restoration of continuity and closure of
the abdomen once the patient is hemodynamically
stable. We refer you to the WSES guidelines on Open
Abdomen management for further information [67].
Antimicrobial therapy
Should antibiotic therapy be prescribed and should
anti-fungal therapy be administrated empirically in
patients with perforated peptic ulcer?
In patients with perforated peptic ulcer, we
recommend the administration broad-spectrum antibi-
otics (strong recommendation based on low-quality ev-
idences, 1C)
We recommend the collection of samples for
microbiological analysis for both bacteria and fungi in
all patients undergoing surgery with subsequent
antibiotic therapy adjustment (strong recommendation
based on low-quality evidences, 1C
We suggest not to administer antifungal agents as
standard empiric therapy in patients with perforated
peptic ulcer. Antifungal should be administrated in
patients at high risk for fungal infection (e.g.,
immunocompromised, advanced age, comorbidities,
prolonged ICU-stay, unresolved intra-abdominal infec-
tions) (weak recommendation based on low-quality ev-
idences, 2C)
The perforation of a peptic ulcer almost invariably leads to
peritonitis due to the spillage of gastroduodenal content into
the peritoneal cavity; this event brings a great burden of mor-
bidity, which ranges from 17% to 63%, and is usually repre-
sented by pulmonary and wound infections [66]. Bacteria
involved in peritoneal sepsis vary according to the etiology of
the peritonitis, including the site of perforation. They are
usually represented by gram-positive, gram-negative as well
as anaerobic species [71]. Samples of peritoneal fluid should
be collected in perforated patients because fungal infections
after perforation are common and are associated with longer
hospital stay, higher rate of surgical site infections (SSI), and
increased mortality, as reported in a prospective study by
Shan and coworkers [72]. In the same way, Prakash and co-
workers [73] demonstrated in a prospective study on 84 pa-
tients undergoing surgery for perforation peritonitis that
mortality was higher in patients having positive peritoneal
fluid cultures (p < 0.001) compared with those with negative
cultures, and in those subjects having mixed bacterial and
fungal positive cultures compared with those with isolated
bacterial cultures (p < 0.001).
Notwithstanding positive peritoneal fungal culture is a
significant risk factor for adverse outcome in patients
with PPU [72, 73], the addition of an antifungal therapy
to a broad-spectrum antibiotic therapy is still a matter of
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debate [74]. While antifungal therapy is recommended
for hospital-acquired infections and in patients critically
ill or severely immunocompromised [75], in case of
community-acquired fungal infection, it has been sug-
gested that antifungal therapy should be reserved for
only clinically severe cases [76].
In a retrospective analysis of 133 patients admitted to
the emergency department for abdominal pain due pep-
tic perforation, Li and coworkers [74] demonstrated that
there was not a statistically significant difference in sur-
vival rate between patients who received antifungal ther-
apy and those who did not and that, on a multivariate
analysis, only shock on admission and an APACHE
score higher than 20 were independent risk factors for a
poor outcome. According to this evidence, antifungal
therapy does not benefit patients suffering from PPU
peritonitis with Candida spp. isolated from peritoneal
fluid cultures in general, and antifungal therapy should
be reserved for patients who are critically ill and/or se-
verely immunocompromised.
In patients with perforated peptic ulcer, which anti-
microbial regimen should be used and what is its cor-
rect duration?
In patients with perforated peptic ulcer, we recommend to
start as soon as possible an empiric broad-spectrum anti-
biotic regimen against a mixture of Gram-negative, Gram-
positive, and anaerobic bacteria, possibly after peritoneal
fluid has been collected (Strong recommendation based on
low-quality evidences, 1C)
In patients with perforated peptic ulcer, we suggest a
short-course (3–5 days or until inflammatory markers
normalize) antibiotic therapy (weak recommendation
based on low-quality evidences, 2C).
Perforated peptic ulcer peritonitis is by definition
poly-microbial. Gram-negative and Gram-positive as
well as anaerobic bacteria and yeasts can be isolated
from peritoneal fluid cultures. Antimicrobial therapy, to-
gether with adequate source control, plays a pivotal role
in the management of patients with peritonitis, especially
in those who are immunocompromised. As stated in a
previous published paper [71], an empiric broad-
spectrum antimicrobial therapy should be started as
soon as possible, and possibly after peritoneal fluid sam-
ple collection, irrespective of the presence of severe sep-
sis or septic shock. In these patients, a de-escalation
approach is warranted, to avoid the onset of microbial
resistances and to promptly treat eventual sepsis. The
empiric antimicrobial regimen should be single or com-
bined, according to the range requirements of antimicro-
bial coverage and the risk factors for major resistance
patterns [76].
Modification of the drug regimen becomes possible
when cultures are available, and clinical status can be bet-
ter assessed. If inflammatory markers do not improve, it is
mandatory to rule out other extra-abdominal sources of
infections or different pathogens [71]. As widely accepted
[71], a beta-lactam/beta-lactamase inhibitor can be used
as first-line therapy in case of intra-abdominal infections,
due to its vigorous in vitro activity against gram-positive,
gram-negative, and anaerobic bacteria [77]. The principles
of empiric antibiotic treatment should be defined accord-
ing to the most frequently isolated bacteria, always taking
into consideration the local trend of antibiotic resistance.
In this era of prevalent drug-resistant microorganisms, the
threat of resistance is a source of major concern that can-
not be ignored. In the past 20 years, incidence of
healthcare-associated IAIs caused by MDROs has risen
dramatically [78], probably in correlation with escalating
levels of antibiotic exposure and increasing frequency of
patients with one or more predisposing conditions, in-
cluding elevated severity of illness, advanced age, degree
of organ dysfunction, low albumin levels, poor nutritional
status, immunosuppression, presence of malignancy, and
other comorbidities. The first step in determining poten-
tial resistance patterns of a given infection is by establish-
ing whether the infection is community-acquired or
healthcare-associated (nosocomial). The spectrum of mi-
croorganisms involved in nosocomial infections is signifi-
cantly broader than in community-acquired infections.
Quinolone resistance, prevalence of ESBL-producing
bacteria, prevalence and mechanisms of carbapenem re-
sistance in the local environment, and the place of re-
cent traveling should be always taken into account when
an antibiotic therapy is administered empirically. Gener-
ally, the most important factors in predicting the pres-
ence of resistant pathogens in intra-abdominal infections
are acquisition in a healthcare setting (particularly if the
patient becomes infected in the ICU or has been hospi-
talized for more than 1 week), corticosteroid use, organ
transplantation, baseline pulmonary or hepatic disease,
and previous antimicrobial therapy [78]. In patients with
IAIs, when patients are not severely ill and when source
control is complete, a short course (3–5 days) of postop-
erative therapy is suggested. In 2015, a prospective study
on appropriate duration of antimicrobial therapy was
published [79]: the study randomized 518 patients with
IAIs and adequate source control to receive antibiotics
until 2 days after the resolution of fever, leukocytosis,
and ileus, with a maximum of 10 days of therapy (con-
trol group), or to receive a fixed course of antibiotics
(experimental group) for 4 ± 1 calendar days. In patients
with intra-abdominal infections who had undergone an
adequate source control procedure, the outcomes after
fixed-duration antibiotic therapy (approximately 4 days)
were similar to those after a longer course of antibiotics
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(approximately 8 days) that extended until after the reso-
lution of physiological abnormalities. In this study, most
patients were not severely ill.
If yeast are isolated in the peritoneal fluid culture, the
antifungal regimen should be selected according to the
clinical and immunological status of the patient, severity
of disease, prior exposure to other antifungal therapies,
and type of infection (community-acquired vs. hospital-
acquired) [80]. The duration of hospital stay is a
concern, because prolonged stay is associated with anti-
fungal resistance of Candida strains [81]. Moreover, bio-
film formation of fungi usually goes along with
significant changes in virulence and resistance because,
once embedded into biofilm, fungi become more pro-
tected against the fungicidal/fungistatic effect of drugs.
Four classes of antifungal drugs are available [82]:
1) Azoles (fluconazole, itraconazole, voroconazole, and
posaconazole), with fungistatic action against most
Candida spp.;
2) Echinocandins (caspofungin, micafungin, anidulafungin),
with fungicidal effect;
3) Polyenes (deoxycholate and liposomal formulations
of amphotericin B), with fungicidal effect but
moderate peritoneal penetration;
4) Flucytosine, only used in combination with another
antifungal agent in difficult-to-treat cases, because
of the high risk of resistance.
Fungistatic drugs should be used in critically ill pa-
tients at low-risk for invasive Candida infections, with-
out prior exposure to azoles, and the therapy should be
administered for 7-10 days or until definitive negative
fluid cultures. In high-risk patients with or without prior
exposure to azoles, echinocandins should be preferred.
The duration of treatment depends on the extent of
organ involvement. If candidemia is detected, the admin-
istration should be prolonged at least 14 days after the
end of episode [82].
Following we report the suggested antibiotic regimens ac-
cording to WSES guidelines on intra-abdominal infections.
Community-acquired
1) Empiric antibiotic regimens for non-critically ill pa-
tients with IAIs and normal renal function:
– Amoxicillin/clavulanate 1.2-2.2 g 6-hourly or ceftri-
axone 2 g 24-hourly + metronidazole 500 mg 6-
hourly or cefotaxime 2 g 8-hourly + metronidazole
500 mg 6-hourly
– In patients with beta-lactam allergy: ciprofloxacin
400 mg 8-hourly + metronidazole 500 mg 6-hourly
– Patients at risk for infection with community-
acquired ESBL-producing Enterobacteriacea: ertape-
nem 1 g 24 hourly or tigecycline 100 mg initial dose,
then 50 mg 12-hourly
2) Empiric antibiotic regimens for critically ill patients
with IAIs and Normal renal function:
– Piperacillin/tazobactam 4.5 g 6-hourly or cefepime 2
g 8-hourly + metronidazole 500 mg 6-hourly
– patients at risk for infection with community-
acquired ESBL-producing Enterobacteriacea: merope-
nem 1 g 8-hourly or doripenem 500 mg 8-hourly or
imipenem/cilastatin 1 g 8-hourly
3) If antifungal therapy is indicated:
– Fluconazole (LD 12mg/kg BW-800 mg; MD 6mg/kg/
day) should be given in critically ill patients, with
community-acquired Candida peritonitis, no prior
azole exposure, low-risk for infections with
fluconazole-resistant Candida spp., as prophylaxis to
prevent invasive infections
– Echinocandin antifungals are recommended as first-
line therapy for invasive infections, and candidemia
in non-neutropenic critically ill patients
– Amphotericin B (3–5 mg/day) should be considered if
alternative therapy is not available or in case of
intolerance to echinocandin or azoles
Healthcare-associated
1) Empiric antimicrobial regimens for non-critically
ill patients with IAIs and normal renal function:
– Piperacillin/tazobactam 4.5 g 6-hourly
– In patients at higher risk for infection with MDROs
including recent antibiotic exposure, patient living in
a nursing home or long-stay care with an indwelling
catheter or postoperative infections
○ Meropenem 1 g 8-hourly +/− ampicillin 2 g 6-
hourly or
○ Doripenem 500 mg 8-hourly +/− ampicillin 2 g 6-
hourly or
○ Imipenem/Cilastatin 1 g 8-hourly or
○ As a carbapenem-sparing regimen piperacillin/
tazobactam 4.5 g 6-hourly + tigecycline 100 mg initial
dose, then 50 mg 12-hourly
2) Empiric antimicrobial regimens for critically ill pa-
tients with IAIs normal renal function
– Meropenem 1 g 8-hourly or
– Doripenem 500 mg 8-hourly or
– Imipenem/cilastatin 1 g 8-hourly
+
– Vancomycin 25–30 mg/kg loading dose then 15–20
mg/kg/dose 8-hourly or
– Teicoplanin 12 mg/kg 12-hourly times 3 loading dose
then 12 mg/kg 24-hourly
3) In patients at risk for infection with vancomycin-
resistant Enterococci (VRE) including patients with
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previous enterococcal infection or colonization, immuno-
compromised patients, patients with long ICU stay, or re-
cent vancomycin exposure:
– Linezolid 600 mg 12-hourly or
– Daptomycin 6 mg/kg 24-hourly
Bleeding peptic ulcer
Diagnosis
In patients with suspected bleeding peptic ulcer,
which biochemical and imaging investigations should
be requested?
In patients with suspected bleeding peptic ulcer, we
recommend blood-typing, determinations of
hemoglobin, hematocrit and electrolytes, and coagula-
tion assessment (strong recommendation based on very
low-quality evidences, 1D).
In patients with suspected bleeding peptic ulcer, when
endoscopy is not available, we suggest performing
contrast-enhanced CT scan (weak recommendation
based on very low-quality evidences, 2D)
Peptic ulcer is still the primary cause of non-variceal
upper gastrointestinal bleeding and hypovolemic shock
or its consequences is a major cause of mortality in
acute upper gastrointestinal bleeding [1, 83]. In the
acute setting, with the suspicion of bleeding peptic
ulcer, blood tests that include blood-typing and cross-
matching with determinations of hemoglobin,
hematocrit, electrolytes, and coagulation assessment
should be performed in all patients. Alteration of co-
agulation with INR greater than 1.5 is associated with
an increased risk of mortality [84].
Data are limited in the literature on the use of CT-
scan in the evaluation of gastrointestinal bleeding.
Given the assumption that gastroscopy is the first
diagnostic step, in patients where it is negative or not
feasible, CT-scan may be a valuable tool to detect the
site and the degree of the bleeding. Otherwise, CT
angiography is the first-line investigation of choice for
undifferentiated major gastrointestinal hemorrhage
(being particularly useful for the localization of small
and large intestinal acute hemorrhage). There are in-
creasing data to suggest that CT-scan should be the
“next step” investigative procedure in cases of active
GI hemorrhage [85, 86].
In patients with suspected bleeding peptic ulcer,
what is the diagnostic role of endoscopy?
In patients with suspected bleeding peptic, ulcer, we
recommend performing endoscopy as soon as possible,
especially in high-risk patients (Strong recommenda-
tion based on low-quality evidences, 1C)
Gastroscopy must take place as soon as possible. Many
studies, including a meta-analysis of randomized con-
trolled trials [87], have shown the role of gastroscopy in
reducing rebleeding, need for surgery, and mortality.
Early endoscopy done within 24 h provides both an ef-
fective therapy of the bleeding and prognostic informa-
tion based on endoscopic stigmata [88, 89].
In patients with bleeding peptic ulcer, are the
endoscopic findings useful to determine the risk for
rebleeding and how do they affect the clinical
management?
We suggest guiding management decisions according to
stigmata of recent hemorrhage during endoscopy
because they can predict the risk of further bleeding
(strong recommendation based on low-quality evi-
dences, 1C)
The gastroscopy findings can be classified using the
modified Forrest classification. With the identification of
lesions with high-risk stigmata, it is possible to stratify
the risk of rebleeding, the need for intervention, and
mortality [89, 90]. Furthermore, gastroscopy is essential
in identifying patients with a low risk that may be dis-
charged early [87, 88]. Numerous scores have been
tested to predict the need for surgery and gastroscopy,
the Glasgow-Blatchford Score (GBS), the Rockall score,
and the AIMS65 being the most widely evaluated and
adopted. Risk stratification should identify high-risk pa-
tients for early intervention and reduce the duration of
hospital stay for low-risk patients [91, 92].
Resuscitation
In patients with bleeding peptic ulcer, which parame-
ters should be evaluated at ED referral and which cri-
teria should be adopted to define an unstable
patient?
We recommend a rapid and careful surgical/medical
evaluation of bleeding peptic ulcer disease patients to pre-
vent further bleeding and to reduce mortality (strong rec-
ommendation based on very low-quality evidences, 1D)
We recommend evaluating several elements (symptoms,
signs, and laboratory findings) to assess the stability/in-
stability of patients with bleeding peptic ulcer at ED re-
ferral (strong recommendation based on low quality
evidences, 1C)
In patients with bleeding peptic ulcer, we suggest evalu-
ating patients according to Rockall and Glasgow-
Blatchford scoring systems to assess the severity of the
disease and to guide therapy (weak recommendation
based on low-quality evidences, 1C).
Bleeding peptic ulcer disease is a clinical emergency
requiring a rapid surgical/medical evaluation to assess
the stability of the clinical picture; the approach is
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similar to the bleeding trauma patient [93]. In this re-
gard, we suggest referring to the last edition of the Euro-
pean guideline on management of major bleeding and
coagulopathy following trauma [94]. The parameters
that should be assessed at ER referral are the same as re-
ported in the American College of Surgeons Advanced
Trauma Life Support (ATLS) (American College of Sur-
geons Committee on Trauma. ATLS® Student Manual
10th Edition; 2018) classification of blood loss (heart
rate, blood pressure, pulse pressure, respiratory rate,
urine output, Glasgow Coma Scale score, and base def-
icit). Moreover, it is very important to take an accurate
medical history [93] especially regarding:
– Drugs and diseases that may affect the coagulation
status (i.e., antiplatelets, anticoagulants, hepatic
failure)
– Cardiac (i.e., coronary artery disease) and pulmonary
diseases that may make patients more susceptible to
adverse effects of anemia
– Neurological diseases (i.e., dementia) that may
predispose patients to pulmonary aspiration of
gastric contents.
Several scoring systems are available for the evaluation
of patients with upper gastrointestinal bleeding. The
Rockall score [95] can be utilized to identify patients at
risk of adverse outcomes where the Glasgow-Blatchford
bleeding score [96] identifies patients needing interven-
tions such as blood transfusions or endoscopy.
In patients with bleeding peptic ulcer, which are
the appropriate targets for resuscitation (hemoglobin
level, blood pressure/heart rate, lactates level,
others)?
We recommend several resuscitation targets, similar to
those of damage control resuscitation in the bleeding
trauma patient (weak recommendation based on low-
quality evidences, 1C).
In patients with bleeding peptic ulcer, we recommend
to maintain an Hb level of at least > 7 g/dl during the re-
suscitation phase (strong recommendation based on
moderate-quality evidences, 1B).
Early resuscitation of patients with upper gastrointes-
tinal bleeding is of paramount importance to reduce
mortality; this must proceed simultaneously with endo-
scopic and surgical procedures [97]. A rapid ABC (air-
way, breathing, and circulation) evaluation should be
done immediately. Appropriate targets for resuscitation
in bleeding peptic ulcer patients can be considered the
same used in bleeding trauma patients (systolic blood
pressure of 90–100 mmHg until major bleeding has
been stopped; normalization of lactate and base deficit;
hemoglobin 7–9 g/dl; correction/prevention of coagu-
lopathy); for this reason, we refer to the
abovementioned guideline [94]. Regarding hemoglobin
level, a randomized controlled trial comparing the effi-
cacy and safety of a restrictive transfusion strategy
(transfusion with an Hb > 7 g/dl) with those of a liberal
transfusion strategy (transfusion with an Hb > 9 g/dl) in
severe acute gastrointestinal bleeding has been per-
formed [98]. The restrictive strategy, compared with
the liberal strategy, has been significantly associated
with a better outcome.
Non-operative management—endoscopic treatment
In patients with bleeding peptic ulcer, which are the
indications for non-operative management?
In patients with bleeding peptic ulcer, we recommend
non-operative management as the first line of manage-
ment after endoscopy (strong recommendation based on
low-quality evidences, 1C).
Non-operative management of bleeding peptic ulcer
incorporates principles of ABCDE [99]:
– Airway control
– Breathing—ventilation and oxygenation
– Circulation—fluid resuscitation and control of
bleeding
– Drugs—pharmacotherapy with PPIs, prokinetics, etc.
– Endoscopy (diagnostic and therapeutic) or
embolization (therapeutic)
A meta-analysis from Barkun et al. [100] that included
forty-one randomized trials showed that all endoscopic
therapies decreased rebleeding versus pharmacotherapy
alone. Endoscopy is indicated to establish diagnosis and
institute therapy for bleeding peptic ulcer [101]. In
acutely bleeding ulcers, endoscopy is a part of
resuscitation.
In patients with bleeding peptic ulcer, which are
the indications for endoscopic treatment?
In patients with bleeding peptic ulcer, we recommend
endoscopic treatment to achieve hemostasis and reduce
re-bleeding, the need for surgery, and mortality (strong
recommendation based on low-quality evidences, 1C).
We suggest stratifying patients based on the Blatchford
score and adopting a risk-stratified management (weak
recommendation based on very low-quality evidences,
2D):
– In the very low-risk group, we suggest outpatient en-
doscopy (weak recommendation based on low-quality
evidences, 2C)
– In the low-risk group, we recommend early inpatient
endoscopy (≤ 24 h of admission) (strong recommen-
dation based on low-quality evidences, 1C).
– In the high-risk group, we recommend urgent in-
patient endoscopy (≤ 12 h of admission) (strong rec-
ommendation based on low-quality evidences, 1C).
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In patients with spurting ulcer (Forrest 1a), oozing
ulcer (Forrest 1b), and ulcer with non-bleeding visible
vessel (Forrest 2a), endoscopic hemostasis is recom-
mended (strong recommendation based on low-quality
evidences, 1C)
In patients with bleeding peptic ulcer, we suggest dual
modality for endoscopic hemostasis (weak recommenda-
tion based on moderate-quality evidences, 2B)
In patients with bleeding peptic ulcer, we suggest con-
sidering Doppler probe–guided endoscopic hemostasis if
expertise is available (weak recommendation based on
very low-quality evidences, 2D).
Endoscopy not only establishes the diagnosis but also
treats the bleeding. WSES advocates patients’ risk deter-
mination by using Blatchford score, Forrest classifica-
tion, and clinical judgment. Three levels of risk
stratification are proposed:
– Very low risk—safe for outpatient management, low
risk of death
– Low risk—need for admission and early endoscopy
– High risk—need for resuscitation and urgent
endoscopy
Risk stratification is based on many risk prediction
models and Blatchford score is one of the most vali-
dated tools. In an international multicenter prospective
study including 3012 patients, Stanley et al. [102] has
shown that Blatchford score of 1 or less (very low-risk
group) had a sensitivity of 98.6%, specificity of 34.6%,
positive predictive value of 96.6%, and a negative pre-
dictive value of 56.0% for non-intervention and survival
both as the combined endpoint. They also reported that
a threshold Blatchford score of 7 or more (high-risk
group) was best at predicting endoscopic treatment,
with a sensitivity of 80.4%, specificity of 57.4%, positive
predictive value of 31.3%, and negative predictive value
of 92.4%. Endoscopy reassures a safe and early dis-
charge in low-risk patients and assists therapy in high-
risk patients. While the timing of endoscopy is deter-
mined by local protocols and resources, the sooner the
better, WSES advocates to perform endoscopy at the
earliest available opportunity regardless of the risk pro-
file and the only limitation would be resources and ex-
pertise. Endoscopy by the “clock” is mere guidance, and
if endoscopy could be done earlier, then a clinician
should do it. Endoscopy is a part of the resuscitative
strategy and blood transfusion should not replace early
hemostasis. Dual modality of endoscopic hemostasis is
advocated in preference to single modality. Marmo
et al. has conducted a meta-analysis [103] including 20
randomized controlled trials and 2472 patients compar-
ing dual therapy versus monotherapy in endoscopic
treatment of high-risk bleeding ulcers and concluded
that dual endoscopic therapy was superior to epineph-
rine injection alone in improving outcomes of patients
with high-risk bleeding ulcers. In a Cochrane review in-
cluding 19 randomized studies and 2033 patients, Ver-
gara et al. [104] has shown that additional endoscopic
treatment after epinephrine injection reduces further
bleeding and the need for surgery in patients with high-
risk bleeding peptic ulcer; however, they cannot con-
clude that a particular form of dual-modality treatment
is equal or superior to another. Shi et al. have per-
formed a network meta-analysis on dual therapy
choices [105] and shown that the addition of mechan-
ical therapy after epinephrine injection significantly re-
duced the probability of rebleeding (OR 0.19, 95% CI
0.07–0.52) and surgery (OR 0.10, 95% CI 0.01–0.50).
Epinephrine with thermal therapy was shown to reduce
the rebleeding rate (OR 0.30, 95% CI 0.10–0.91) but
not the need for surgical intervention (OR 0.47, 95% CI
0.16–1.20). Hence, it appears that mechanical therapy
along with epinephrine injection is adequate. In pa-
tients with adherent clot (Forrest 2b), WSES advocates
non-aggressive clot irrigation-flushing attempts rather
than mechanical dislodgment. The Asia-Pacific Work-
ing Group consensus advocates vigorous target irriga-
tion for at least 5 min and dual-modality hemostasis for
patients with adherent clots [106]. We advocate a cau-
tious approach for dislodging the adherent clots. If ex-
pertise is available, a vigorous approach could be
adopted [107]. The individual endoscopist should be at
the liberty to make decisions and we propose individual
judgment until further evidence is available to support
that clot dislodgment improves outcomes. In the event
of bleeding, therapy is strongly advocated. Newer mo-
dalities such as over the scope clips (OTSC), hemos-
pray, EUS-guided ultrasound angiography, RFA,
Endoclot, endoscopic band ligation, cryotherapy, Anka-
ferd blood stopper, and endoscopic suturing devices are
available. Their role needs to be defined. There are six
studies that have investigated the role of over the scope
clips either as first-line or as second-line therapy for re-
fractory bleeding [108–113]. Doppler probe–guided le-
sion assessment is more accurate than endoscopic
scoring of predicting rebleeding risk. In a prospective
cohort study including 163 patients, Jensen et al.
showed spurting (Forrest 1a), visible vessel (Forrest 2a),
and adherent clot (Forrest 2b) have a higher Doppler
flow compared with oozing (Forrest 1b); Doppler as-
sessment improved risk stratification [114]. It is im-
portant to note that rebleeding risk prediction is
superior to Forrest classification system, i.e., Forrest 1b
has low risk of rebleeding compared with Forrest 2a
and Forrest 2b lesions. Doppler probe–guided lesion
management is shown to reduce rebleeding and further
intervention. In a single blinded randomized controlled
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study including 148 patients with 125 ulcers, Jensen
et al. has shown that Doppler probe–guided endoscopic
hemostasis significantly reduced 30-day rates of
rebleeding compared with standard, visually guided
hemostasis with the number needed to treat of 7 [115].
In patients with bleeding peptic ulcer, what is the
appropriate pharmacological regimen (erythromycin,
PPI, terlipressin, others)?
In patients with bleeding peptic ulcer, we suggest ad-
ministering pre-endoscopy erythromycin (weak recom-
mendation based on moderate-quality evidences, 2B).
In patients with bleeding peptic ulcer, we suggest start-
ing PPI therapy as soon as possible (weak recommenda-
tion based on moderate-quality evidences, 2B),
In patients with bleeding peptic ulcer, after successful
endoscopic hemostasis, we suggest administration of high-
dose PPI as continuous infusion for the first 72 h (weak
recommendation based on moderate-quality evidences,
2B).
In patients with bleeding peptic ulcer, we recommend
PPI for 6–8 weeks following endoscopic treatment. Long-
term PPI is not recommended unless the patient has on-
going NSAID use (strong recommendation based on
moderate-quality evidences, 1B)
The role of acid suppression in the treatment of pep-
tic ulcer and its complications is well known [116], but
the dosage and the duration of PPI administration for
the treatment of bleeding peptic ulcer are still a matter
of debate. Multiple studies highlighted that high-dose
regimens of PPI [117] reduce rebleeding, surgical inter-
vention, and mortality following endoscopic hemostasis.
In a randomized placebo-controlled trial of 767 patients
with peptic ulcer bleeding treated with endoscopic
therapy because of high-risk stigmata, high-dose intra-
venous PPIs (80 mg of esomeprazole bolus plus 8 mg/h
of continuous infusion for 72 h) significantly reduced
rebleeding (5.9% vs. 10.3%, p = 0.03) and the need for
endoscopic retreatment [118]. Similar results were
found by meta-analysis; high-dose intravenous PPIs
after endoscopic therapy significantly reduced rebleed-
ing, need for surgery, and mortality compared with pla-
cebo/no therapy [119]. On the other hand, a Cochrane
review [120] focusing on this topic and including
twenty-two RCTs found insufficient evidence to con-
clude superiority, inferiority, or equivalence of high-
dose PPI treatment over lower doses in peptic ulcer
bleeding. Another systematic review from the Cochrane
Collaboration [121] included six RCTs comprising 2223
patients and showed that PPI treatment initiated before
endoscopy for upper gastrointestinal bleeding might re-
duce the proportion of patients with stigmata of recent
bleeding at index endoscopy and significantly reduces
the requirement for endoscopic therapy during index
endoscopy. However, this study found no evidence that
PPI treatment affects clinically important outcomes,
namely mortality, rebleeding, or need for surgery. In
the light of the above, the administration of high-dose
PPI, starting prior to endoscopy and continuing for the
first 72 h, seems reasonable and could be suggested,
even though further studies are needed to give a strong
recommendation. However, the use of proton-pump in-
hibitors should not replace urgent endoscopy in pa-
tients with active bleeding.
A prokinetic drug given before endoscopy helps to
empty stomach contents and improves viewing at endos-
copy. Only five randomized trials and their pooled ana-
lyses have been published: three with the use of
erythromycin and two with metoclopramide [122]. Pre-
endoscopy erythromycin has been extensively studied
and shown to enhance the visualization as well as reduce
the need for second endoscopy [123, 124]. However,
such practice has not shown to reduce the need for sur-
gical intervention or impact mortality [125].
After initial hemostasis, the risk of rebleeding must
be minimized by adjunct therapies. In patients who
have PPU complicated by bleeding, there is a 33%
risk of rebleeding in 1–2 years. Furthermore, there is
a 40–50% rebleeding risk over the subsequent 10
years following the initial episode of bleeding [126].
PPIs are recommended for 6–8 weeks following endo-
scopic treatment of peptic ulcer bleeding to allow
mucosal healing [127]. Once mucosal healing has
been achieved, how long PPIs should be continued is
still controversial. Randomized prospective trials have
demonstrated a benefit to long-term acid-suppression
therapy in two settings: chronic NSAID users and H.
pylori-infected patients [128]. Testing for H. pylori is
recommended in all patients with BPU. This should
be followed by eradication therapy for those who are
H. pylori positive, with subsequent assessment of the
effect of this therapy, and renewed treatment in those
in whom eradication fails.
In patients with recurrent bleeding from peptic
ulcer, what is the role of non-operative management?
In patients with recurrent bleeding from peptic ulcer,
we recommend endoscopy as a first-line treatment (strong
recommendation based on low-quality evidences, 1C).
In patients with recurrent bleeding, we suggest trans-
catheter angioembolization as an alternative option
where resources are available (weak recommendation
based on very low-quality evidences, 2D).
Emergency endoscopy is the first-line management for
rebleeding peptic ulcer [129]. Such endoscopy must be
done at the earliest available opportunity. In patients
who are hemodynamically stable, angioembolization of
the bleeding vessel is an option. However, this should be
carefully balanced for its inherent risks of patient trans-
fer, contrast nephropathy, pancreatitis, or cholecystitis
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risk due to embolization material and risks associated
with vascular access.
Angiography, embolization
In patients with bleeding peptic ulcer, which are the
indications for angiography?
In patients with bleeding peptic ulcer, we suggest con-
sidering angiography for diagnostic purposes as a second-
line investigation after a negative endoscopy (weak rec-
ommendation based on low-quality evidences, 2C).
No recommendation can be made regarding the role of
provocation angiography.
Angiography may assist both the diagnosis and the
treatment of hemorrhage associated with peptic ulcer dis-
ease. However, endoscopy remains the first-line investiga-
tion of choice for an undifferentiated upper
gastrointestinal hemorrhage [130]. Similarly, endoscopy is
the first-line diagnostic modality for patients with sus-
pected upper gastrointestinal hemorrhage from ulcer dis-
ease [130].
Angiography for diagnostic purposes is a second-line in-
vestigation and angiography before endoscopy results in
unacceptable rates of negative investigations and is not
warranted given the invasive nature of an angiogram.
Angiography is useful for the confirmation and
localization of the point of hemorrhage and allows treat-
ment by embolization. On occasion, provocation angiog-
raphy with the use of anticoagulants may be indicated. An
inter-specialty consensus should guide this investigation
on a case by case basis. Only case reports, case series, and
expert opinion are available to guide this decision-making.
In patients with bleeding peptic ulcer, which are
the indications for angioembolization?
In hemodinamically stable bleeding peptic ulcer pa-
tients, where endoscopic hemostasis fails twice or is not
possible/feasible, we suggest angiography with angioem-
bolization where technical skills and equipment are
available (weak recommendation based on very low-
quality evidences, 2D)
Endoscopy is the established first-line therapy for the
management of hemorrhage associated with peptic ulcer
disease. It is appropriate (high-level evidence), to also
conduct a second endoscopic examination with thera-
peutic intent, in cases of recurrent hemorrhage. How-
ever, where this also fails, surgery has been traditionally
indicated. These operations are reported to be associated
with mortality rates as high as 40% [129, 131]. Because
of this high postoperative mortality, other strategies have
been sought and angioembolization has become increas-
ingly described during the past two decades.
High-risk surgical patients have been suggested and
recommended as the ideal candidates for angioemboliza-
tion [130, 132]. However, no specific data exist investi-
gating or defining the definition of “high risk.”
Interdisciplinary consensus (surgery, gastroenterology,
intensive care, anesthesia) is required to guide this
decision-making. Low-risk surgical patients are likely to
benefit from an operative strategy due to the likely re-
duced mortality in this group. No specific studies exist
to validate this claim.
Furthermore, according to the physiology behind
wound repair, it is possible that angioembolization could
complicate a subsequent surgical intervention because of
the reduction in the blood flow of the operative field,
but no specific data exists to validate this claim.
Should embolization be considered for unstable pa-
tients with bleeding peptic ulcer?
We suggest against a routinely use of angioemboliza-
tion unstable patients. Angioembolization in unstable pa-
tients could be s considered only in selected cases and in
selected facilities (weak recommendation based on very
low-quality evidences, 2D).
There are no specific data to address the relative safety
of angioembolization compared with surgery in
hemodynamically unstable patients. Variable definitions
of hemodynamic stability between studies further com-
plicate meaningful recommendations in this field. Suc-
cessful reports of angioembolization in patients with
hemorrhagic shock are described. A recent retrospective
case series describing super-selective angioembolization
in 51 patients with active gastrointestinal hemorrhage
(with 57% of these upper gastrointestinal in nature),
demonstrated the possibility of this approach in patients
with physiological shock (defined in this study as a sys-
tolic blood pressure of < 90mmHg) [133].
The appropriateness of angioembolization in
hemodynamically unstable patients depends on a num-
ber of factors, including the timely availability and skills
of the angioembolization service, the quality of the initial
and ongoing resuscitation, the quality of the peri-
procedural and post-procedural intensive care, and pa-
tient variables. Furthermore, the presence of a hybrid
OR or strict proximity of OR and the angioembolization
facility is mandatory for the angiographic approach to
unstable patients. A coordinated, interdisciplinary ap-
proach (surgery, interventional radiology, gastroenter-
ology, intensive care, and anesthesia) is likely to benefit
these critically ill patients, although there are no specific
data to validate this hypothesis.
In patients with recurrent bleeding peptic ulcer,
which are the indications for angioembolization?
In patients with rebleeding peptic ulcer, we suggest
angioembolization as a feasible option (weak recommen-
dation based on low-quality evidences, 2C).
For recurrent bleeding (defined as re-bleeding after
2 endoscopic therapeutic attempts), angioembolization
and surgical options should be considered. Multiple
reports and case series of successful angioembolization
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of hemorrhage from gastroduodenal ulcer disease are
reported [134]. However, no high-level studies com-
paring the outcomes for angioembolization with sur-
gery exist. One prospective and multiple retrospective
cohort studies comparing outcomes between patients
undergoing angioembolization with those undergoing
surgery for rebleeding after failed endoscopic control
are available. These studies were summarized in three
meta-analysis [135–137]. Kyaw et al. summarized 6
retrospective cohort studies: surgery was found to sig-
nificantly reduce the likelihood of further (post-inter-
vention) hemorrhage, and was associated with a trend
towards a reduced need for further intervention. How-
ever, surgery was also associated with a trend to in-
creased mortality. Beggs et al. included 9 cohort
studies (8 retrospective and 1 prospective), and simi-
larly concluded that surgery was associated with a sig-
nificantly lower risk of rebleeding, and only a marginal
trend towards increased mortality. Subsequent to
these first two meta-analyses, a case-control study
comparing angioembolization with surgery [138] re-
ported a trend to higher rebleeding rates following
angioembolization, and a trend towards higher mortal-
ity after surgery was seen. A significantly lower rate of
post-procedural complications was reported in the
angioembolization cohort. The latest meta-analysis
[137] found similar results, but interestingly found a
slight drift toward a lower mortality for the angioem-
bolization group.
In patients with bleeding peptic ulcer who under-
went angioembolization, which are the most appro-
priate embolization techniques and materials?
Varied techniques and materials exist for the use in the
embolization of bleeding duodenal ulcer disease. A tai-
lored approach, guided by the multidisciplinary team, in-
corporating patient, pathology, and environmental
factors is suggested (weak recommendation based on low-
quality evidences, 2C).
Successful embolization of gastric and duodenal arter-
ies is complicated by the rich collateral blood supply.
Several technical points are raised in various case re-
ports, series, and review articles in this field. There are
no high-level articles to guide these technical consider-
ations. Pre-procedural endoscopic localization of the
point of hemorrhage could assist guidance of the select-
ive and super-selective angiography and the angiogram
can be further guided by the placement of an endoscopic
clip at the ulcer if this has been identified. Diagnostic
angiography usually commences with a selective coeliac
axis and superior mesenteric artery catheterization and
angiogram. Where no extravasation is seen, a super-
selective approach normally follows. Imaging from both
aspects of the bleeding point is ideally obtained (both
sides need to be approached).
In patients with bleeding peptic ulcer and non-
evident bleeding during angiography, is there a role
for prophylactic embolization?
No recommendation can be made on the role of
prophylactic embolization.
Prophylactic embolization may be considered in two
situations
– Empirically, at the time of a negative angiogram:
Several authors have suggested a role for blind
embolization for upper gastrointestinal hemorrhage,
noting that these patients had similar outcomes to
patients who underwent embolization after the
demonstration of a point of hemorrhage [134, 139,
140]. A variation on this uses the endoscopic
information to guide the area for embolization [141,
142]. However, these approaches are based on
retrospective cohorts. There are insufficient high-
level data to draw firm conclusions.
– As a planned intervention, in association with
endoscopic control: The addition of prophylactic
embolization in addition to endoscopic hemostasis
has been investigated by several authors, including
most recently with two randomized controlled trials
[143, 144]. Laursen et al. demonstrated a trend
toward improved outcomes in patients who
underwent additional prophylactic embolization.
However, the second RCT by Lau et al. failed to
confirm this observation. This approach was also
supported by a retrospective series by Mille et al.
[145].
At present, the evidences available in the literature ap-
pear to be insufficient to routinely recommend this
approach.
Surgery
In patients with bleeding peptic ulcer, which are the
indications for surgical treatment and which is the
appropriate timing for surgery?
In patients with bleeding peptic ulcer, we suggest surgi-
cal hemostasis (or angiographic embolization if immedi-
ately available and with appropriate skills) after failure
of repeated endoscopy. In patients with hypotension and/
or hemodynamic instability and/or ulcer larger than 2
cm at first endoscopy, we suggest surgical intervention
without repeated endoscopy (strong recommendation
based on very low-quality evidences, 1D).
A renowned RCT conducted in 1999 [129] compared
endoscopic retreatment with surgery for peptic ulcer
rebleeding after initial endoscopy. Over a 40-month
period, 92 patients with recurrent bleeding were en-
rolled: 48 patients were randomly assigned to undergo
immediate endoscopic retreatment and 44 were assigned
Tarasconi et al. World Journal of Emergency Surgery            (2020) 15:3 Page 17 of 24
to undergo surgery. Of the 48 patients who were
assigned to endoscopic retreatment, 35 had long-term
control of bleeding. Thirteen underwent salvage surgery,
11 because retreatment failed, and 2 because of perfora-
tions resulting from thermocoagulation. Five patients in
the endoscopy group died within 30 days, as compared
with eight patients in the surgery group (p = 0.37). Seven
patients in the endoscopy group had complications, as
compared with 16 in the surgery group (p = 0.03). Dur-
ation of hospitalization, need for ICU admission, ICU
length of stay, and the number of blood transfusions
were similar in the two groups. In multivariate analysis,
hypotension at randomization (p = 0.01) and an ulcer
size of at least 2 cm (p = 0.03) were independent factors
predictive of the failure of endoscopic retreatment. Ac-
cording to these data, repeated endoscopy is indicated
for stable patients with ulcers smaller than 2 cm in
diameter, while for patients with a larger ulcer and heav-
ier bleeding, surgery may be taken into account as a
first-line therapy.
No evidence is available regarding the impact on clin-
ical outcome of time before surgery for bleeding peptic
ulcer. We suggest immediate surgery for unstable pa-
tients with bleeding peptic ulcer refractory to endos-
copy/angioembolization.
In patients with bleeding peptic ulcer, what is the
most appropriate surgical approach (open vs laparos-
copy) and what are the most appropriate surgical
procedures?
In patients with refractory bleeding peptic ulcer, we
suggest surgical intervention with open surgery (weak rec-
ommendation based on very low-quality evidences, 2D).
In patients operated for bleeding peptic ulcer, we sug-
gest intra-operative endoscopy to facilitate the
localization of the bleeding site (weak recommendation
based on very low-quality evidences, 2D).
We suggest choosing the surgical procedure according
to the location and extension of the ulcer and the charac-
teristics of the bleeding vessel (weak recommendation
based on low-quality evidences, 2C)
An immediate or delayed biopsy is recommended (weak
recommendation based on low-quality evidences, 2C)
A refractory bleeding peptic ulcer is defined as an
ulcer still bleeding after repeated endoscopy/angioembo-
lization. Open surgery is recommended when endo-
scopic treatments have failed and there is evidence of
ongoing bleeding, plus or minus hemodynamic instabil-
ity. The choice of the appropriate surgical procedure for
bleeding peptic ulcer should be made on the basis of the
location and extension of the ulcer and the characteris-
tics of the bleeding vessel. Surgical approach involves
ulcer oversew or resection. Bleeding gastric ulcers
should be resected or at least biopsied for the possibility
of neoplasms. Conversely, most duodenal ulcers
requiring surgery for persistent bleeding are usually large
and posterior lesions, and the bleeding is often from the
gastro-duodenal artery. A recent prospective cohort
study conducted in Denmark [146] compared the out-
comes of duodenal and gastric bleeding peptic ulcers
and found a significantly higher 90-day mortality and re-
operation rate for the duodenal location, confirming the
greater complexity of surgical management of this ulcer.
Via duodenotomy, the bleeding vessel can be seen on
the floor of the ulcer and can be rapidly oversewn. It is
critical to perform triple-loop suturing of bleeding of the
GDA due to the collateral blood supply to the transverse
pancreatic arteries. The surgeon may not know pre-
operatively where the bleeding originates and intraopera-
tive endoscopic guidance may be helpful. For patients
with intractable ulcer bleeding, Schroeder et al. [147]
from the analysis of a large database (ACS-NSQIP) have
found that the surgical procedure of vagotomy/drainage
is associated with significantly lower mortality than sim-
ply simple local ulcer oversew. They further suggest that
vagotomy/drainage is preferred to local procedures alone
for the surgical management of patients with bleeding
peptic ulcer disease requiring emergency operation for
intractable bleeding ulcers.
In patients with bleeding peptic ulcer, what is the
role of damage control surgery?
We suggest considering damage control surgery for pa-
tients with hemorrhagic shock and signs of severe physio-
logical derangement, in order to quickly resolve the
bleeding and allow a prompt ICU admission (weak rec-
ommendation based on very low-quality evidences, 2D).
Indications for damage control surgery in bleeding
peptic ulcer are similar to those for perforated peptic
ulcer and are reported in the WSES guidelines on Open
Abdomen management in non-trauma patients [67].
Antimicrobial therapy
In patients with bleeding peptic ulcer, which are the
indications for antimicrobial therapy and for Helico-
bacter pylori testing?
In patients with bleeding peptic ulcer, empirical anti-
microbial therapy is not recommended (strong recom-
mendation based on low-quality evidences, 1C)
We recommend performing Helicobacter pylori testing
in all patients with bleeding peptic ulcer (strong recom-
mendation based on low-quality evidences, 1C).
Bleeding peptic ulcer accounts for 75% of patients ad-
mitted to ED for peptic ulcer disease [148] and has dif-
ferent etiologies (ulcerogenic medications such as
acetylsalicylic acid and NSAIDs, H. pylori infection, etc).
H. pylori infection has a variable prevalence of 20–50%
among patients with bleeding peptic ulcer in various
countries, but its eradication is associated with a signifi-
cant reduction in ulcer recurrence rate and rebleeding
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[66, 149–151]. In a systematic review, Gisbert et al.
showed a 26% rebleeding rate among patients with H.
pylori infection–associated bleeding ulcers who did not
receive eradication therapy [150]. Conflicting results are
reported about appropriate timing to start eradication
therapy. Empirical eradication therapy immediately after
re-feeding has been suggested as the most cost-effective
strategy [151], but its real effectiveness can vary by re-
gional prevalence of the bacteria. Therefore, confirming
the result of H. pylori test and initiating eradication ther-
apy in H. pylori-positive patients prior to discharge
would appear to be a more appropriate strategy than to
apply empirical therapy to all patients with BPU [66,
152].
For this reason, all patients having BPU should
undergo H. Pylori testing. Different tests are available to
confirm H. pylori infection. The urea breath test (UBT)
and stool antigen testing are acceptable non-invasive
tests with a sensitivity of 88–95% for UBT and 94% for
stool antigen testing, respectively. Specificity is 95–100%
for UBT and 92% for stool antigen testing, respectively
[151]. In cases of bleeding peptic ulcer, H. pylori testing
on endoscopic tissue biopsy may be available [151].
In patients with bleeding peptic ulcer and positive
tests for HP infection, which are the therapeutic
options?
In H. pylori-positive BPU patients, eradication therapy
is recommended to avoid recurrent bleeding (strong rec-
ommendation based on low-quality evidences, 1C)
In patients with HP positive tests, standard triple ther-
apy (amoxicillin, clarithromycin, and PPI) regimen is rec-
ommended as first-line therapy if low clarithromycin
resistance is present (strong recommendation based on
moderate-quality evidences, 1B)
10 days of sequential therapy with four drugs (amoxi-
cillin, clarythromicin, metronidazole, and PPI) is recom-
mended in selected cases, if compliance to the scheduled
regimen can be maintained, and if clarithromycin high
resistance is detected (strong recommendation based on
low-quality evidences, 1C).
In patients with HP positive tests, a 10-day
levofloxacin-amoxicillin triple therapy is recommended
as second-line therapy if first-line therapy failed (strong
recommendation based on moderate-quality evidences,
1B).
We recommend to start standard triple therapy (STT)
after 72–96 h of intravenous administration of PPI and
to administer it for 14 days (strong recommendation
based on low-quality evidences, 1C)
The worldwide prevalence of H. pylori infections is ap-
proximately 50%, with the highest being in developing
countries [153]. Standard treatments for H. pylori infec-
tions have been endorsed by Western scientific societies,
and by regulatory authorities relying on clarithromycin,
metronidazole, or amoxicillin in conjunction with PPI
[154].
As the response to eradication therapy is significantly
related to the prevalence of primary resistance in the
population, the choice of treatment regimen should be
based on the knowledge of the underlying prevalence of
resistant strains in the community [151–154].
Several international guidelines [151, 152] and avail-
able meta-analysis [153, 154] recommend that standard
triple therapy (amoxicillin, clarithromycin, and PPI) regi-
men should be used as first-line therapy if low clarithro-
mycin resistance is present. The suggested doses are:
– PPI standard dose twice a day;
– Clarithromycin 500 mg twice a day;
– Amoxicillin 1000 mg twice a day, or
– Metronidazole 500 mg twice a day.
Sequential therapy with four drugs (amoxicillin, clari-
thromycin, metronidazole, and PPI) should be consid-
ered in selected cases, if compliance to the scheduled
regimen can be maintained, and if clarithromycin high
resistance is detected. It is defined as the use of one PPI
and amoxicillin for the first 5 days followed by PPI plus
clarithromycin and metronidazole for the next 5 days
[155]. Recommended doses are as follows:
– PPI standard dose twice a day;
– Amoxicilllin 1000 mg twice a day;
– Clarithromycin 500 mg twice a day;
– Metronidazole 500 mg twice a day.
If any of these regimens failed, a second-line therapy is
represented by a 10-day levofloxacin-amoxicillin triple
therapy. The suggested doses are:
– PPI standard dose twice a day;
– Levofloxacin 500 mg once a day or 250 twice a day;
– Amoxicillin 1000 mg twice a day.
Conclusions
Peptic ulcer disease is still common among the world
population and its incidence pattern is evolving in rela-
tion to the rise of new risk factors, i.e., the increasing
incidence of the Helicobacter pylori infection, the ex-
tensive use of NSAIDs and the increase in alcohol and
smoking abuse. Despite the tremendous improvement
in preventive therapies, the rate of complication of this
disease is still high and is burdened by high morbidity
and mortality. Prompt recognition and treatment of the
complications lead invariably to a better outcome, espe-
cially in elderly and frail patients. For this reason, these
guidelines present evidence-based international consen-
sus statements on the management of complicated
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peptic ulcer from a collaboration of a panel of experts
and are intended to improve the knowledge and the
awareness of physicians around the world on this spe-
cific topic. We divided our work into two main topics,
bleeding and perforated peptic ulcer, and structured it
into six main topics that cover the entire management
process of patients with complicated peptic ulcer, from
diagnosis at ED arrival to post-discharge antimicrobial
therapy, to provide an up-to-date and easy-to-use tool
that can help physicians and surgeons during the
decision-making process.
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